Selonsertib

Drug Profile

Selonsertib

Alternative Names: ASK1 inhibitor - Gilead Sciences; GS-4977; GS-4997

Latest Information Update: 09 Mar 2017

Price : $50

At a glance

  • Originator Gilead Sciences
  • Class Cardiovascular therapies
  • Mechanism of Action MAP kinase kinase kinase 5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-alcoholic steatohepatitis
  • Phase II Alcoholic hepatitis; Diabetic nephropathies; Non-alcoholic fatty liver disease; Pulmonary arterial hypertension

Most Recent Events

  • 27 Feb 2017 Gilead Sciences has patent protection for selonsertib in USA and Europe (Gilead Sciences 10-K, February 2017)
  • 01 Feb 2017 Phase-III clinical trials in Non-alcoholic steatohepatitis in USA (PO) (NCT03053063)
  • 01 Dec 2016 Gilead Sciences completes the phase II ARROW trial in Pulmonary arterial hypertension in USA, United Kingdom, the Netherlands, Canada, France, Germany, Italy and Spain (NCT02234141)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top